(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 16 December 2004 (16.12.2004)

PCT

(10) International Publication Number WO 2004/108938 A3

(51) International Patent Classification⁷: C12N 15/861, C07K 7/06, A61K 48/00

(21) International Application Number:

PCT/GB2004/002421

(22) International Filing Date: 7 June 2004 (07.06.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

03 13132.3

6 June 2003 (06.06.2003) GB

(71) Applicant (for all designated States except US): ICH PRODUCTIONS LIMITED [GB/GB]; 30 Guilford Street, London WC1N 1EH (GB).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): HART, Stephen, Lewis [GB/GB]; Institute of Child Health, 30 Guilford Street, London WC1N 1EH (GB). WRITER, Michele [GB/GB]; Institute of Child Health, 30 Guilford Street, London WC1N 1EH (GB).
- (74) Agents: SILVESTON, Judith et al.; Abel & Imray, 20 Red Lion Street, London WC1R 4PQ (GB).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 12 May 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PEPTIDE LIGANDS OF DENDRITIC CELLS FOR NUCLEIC ACID VECTOR TARGETING

(57) Abstract: A peptide consisting of or comprising an amino acid sequence selected from a) $Px^1X^2X^3$ T [SEQ.ID.NO.:1]; b) PSX⁴S [SEQ.ID.NO.:2]; C) $QX^5X^6X^7Q$ [SEQ.ID.NO.:3]; d) SX^8S [SEQ-ID.NO.:4], in which X^1 , X^2 and X^3 , which may be the same or different, each represents an amino acid residue; X^2 is preferably N or L; X^4 represents an amino acid residue, preferably N or L; X^5 and X^7 , which may be the same or different, each represents an amino acid residue, X^6 represents an amino acid residue having an amide side chain; and X^8 represent an amino acid having an aliphatic side chain, which peptide binds to dendritic cells and also to other types of cells. The peptide may be used a target non-viral and viral vectors to such cells.





Interi al Application No
PCT/GB2004/00242

PCT/GB2004/002421 A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12N15/861 C07K7/06 A61K48/00 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) C12N C07K IPC 7 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, CHEM ABS Data C. DOCUMENTS CONSIDERED TO BE RELEVANT Category ^c Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. IVANENKOV VASILY V ET AL: "Targeted X 1-15, delivery of multivalent phage display 30-107 vectors into mammalian cells" BIOCHIMICA ET BIOPHYSICA ACTA, AMSTERDAM, NL, vol. 1448, no. 3, 11 January 1999 (1999-01-11), pages 463-472, XPO02157575 ISSN: 0006-3002 abstract; page 463, right-hand column, 1-15, lines 3-6; table 1, third peptide 30-107 X WO 98/44121 A (MEHTALI MAJID; LEGRAND 1-15, VALERIE (FR); TRANSGENE SA (FR); BOULANGER 30-107 PIE) 8 October 1998 (1998-10-08) abstract; Seq. ID 1; paragraph joining pages 4 and 5; page 10, lines 14-17; claims 3,6-8,29,33-34 -/--Further documents are listed in the continuation of box C. Patent family members are listed in annex. Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance invention "E" earlier document but published on or after the International "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to "L" document which may throw doubts on priority claim(s) or which is clted to establish the publication date of another citation or other special reason (as specified) involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the "O" document referring to an oral disclosure, use, exhibition or document is combined with one or more other such docuother means ments, such combination being obvious to a person skilled "P" document published prior to the International filling date but later than the priority date claimed in the art. "&" document member of the same patent family Date of the actual completion of the International search Date of mailing of the International search report 0 1 03 05 4 November 2004 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,

Fausti, S

Fax: (+31-70) 340-3016

Intern: Application No
PCT/GB2004/002421

ment, with indication, where appropriate, of the relevant passages 257445 A (MURUGANANDAM ARUMUGAM; IROVIC DANICA (CA); NARANG SARAM N) 25 July 2002 (2002-07-25) ct; table 1, Seq. IDs 61,82; claims 204646 A (O'MAHONY DANIEL J; N DAVID (IE); BYRNE DARAGH (IE)) uary 2003 (2003-01-16) ct; table 4, the 29th peptide on 0 45 251 A (UNIV EBERHARD KARLS) n 2000 (2000-03-09) ct; page 2, lines 21-29; Seq. IDs 1, 40 on pages 6-7 ET AL: "Design and synthesis of and selective alpha(4)beta(7) in antagonists" L OF MEDICINAL CHEMISTRY, AMERICAN AL SOCIETY. WASHINGTON, US, 4, 26 July 2001 (2001-07-26), pages 592, XP002214393 30022-2623	1-15, 30-107 1-15, 30-107 1-15, 30-107
257445 A (MURUGANANDAM ARUMUGAM; IROVIC DANICA (CA); NARANG SARAM N) 25 July 2002 (2002-07-25) ct; table 1, Seq. IDs 61,82; claims 2004646 A (O'MAHONY DANIEL J; N DAVID (IE); BYRNE DARAGH (IE)) ct; table 4, the 29th peptide on 2005; table 4, the 29th peptide on 2000 (2000-03-09) ct; page 2, lines 21-29; Seq. IDs 1, 40 on pages 6-7 ET AL: "Design and synthesis of and selective alpha(4)beta(7) in antagonists" L OF MEDICINAL CHEMISTRY, AMERICAN AL SOCIETY. WASHINGTON, US, 4, 26 July 2001 (2001-07-26), pages 592, XP002214393 20022-2623	1-15, 30-107 1-15, 30-107 1-15, 30-107
IROVIC DANICA (CA); NARANG SARAM N) 25 July 2002 (2002-07-25) ct; table 1, Seq. IDs 61,82; claims 2004646 A (O'MAHONY DANIEL J; N DAVID (IE); BYRNE DARAGH (IE)) uary 2003 (2003-01-16) ct; table 4, the 29th peptide on 2005 (2000-03-09) ct; page 2, lines 21-29; Seq. IDs 1, 40 on pages 6-7 ET AL: "Design and synthesis of and selective alpha(4)beta(7) in antagonists" L OF MEDICINAL CHEMISTRY, AMERICAN AL SOCIETY. WASHINGTON, US, 4, 26 July 2001 (2001-07-26), pages 592, XP002214393 20022-2623	30-107 1-15, 30-107 1-15, 30-107
N DAVID (IE); BYRNE DARAGH (IE)) Lary 2003 (2003-01-16) Lt; table 4, the 29th peptide on 45 251 A (UNIV EBERHARD KARLS) L 2000 (2000-03-09) Lt; page 2, lines 21-29; Seq. IDs 1, 40 on pages 6-7 ET AL: "Design and synthesis of and selective alpha(4)beta(7) in antagonists" L OF MEDICINAL CHEMISTRY, AMERICAN AL SOCIETY. WASHINGTON, US, 4, 26 July 2001 (2001-07-26), pages 592, XP002214393	1-15, 30-107 1-15,
t; page 2, lines 21-29; Seq. IDs 1, 40 on pages 6-7 ET AL: "Design and synthesis of and selective alpha(4)beta(7) in antagonists" L OF MEDICINAL CHEMISTRY, AMERICAN AL SOCIETY. WASHINGTON, US, 4, 26 July 2001 (2001-07-26), pages 592, XP002214393	30-107 1-15,
and selective alpha(4)beta(7) in antagonists" L OF MEDICINAL CHEMISTRY, AMERICAN AL SOCIETY. WASHINGTON, US, 4, 26 July 2001 (2001-07-26), pages 592, XP002214393	
ct; page 2586, paragraph joining and right-hand columns; tables 1-2	1-15, 30-83, 97-107
008537 A (CTL IMMUNOTHERAPIES CORP) uary 2003 (2003-01-30) ct; Seq. IDs 393,394,398,399,537,538 le 1C.	1-15, 30-34
18010 A (INST MEDICAL W & E HALL; RNE LTD (AU); MACFARLANE BURNET) 28 November 1991 (1991-11-28) ct; table 2, 4th peptide	1-15, 30-34
54347 A (HART STEPHEN LEWIS; INST LD HEALTH (GB)) mber 1998 (1998-12-03) in the application ct; page 5, line 22 to page 10, line aim 47	1-15, 30-83, 97-107
072616 A (ICH PRODUCTIONS LTD; MICHELE (GB); HART STEPHEN LEWIS 19 September 2002 (2002-09-19) ct; page 5, lines 2-7; examples 1-2; 21-81	1-15, 30-107
	RNE LTD (AU); MACFARLANE BURNET) 28 November 1991 (1991-11-28) ct; table 2, 4th peptide 54347 A (HART STEPHEN LEWIS; INST LD HEALTH (GB)) mber 1998 (1998-12-03) in the application ct; page 5, line 22 to page 10, line aim 47 972616 A (ICH PRODUCTIONS LTD; MICHELE (GB); HART STEPHEN LEWIS 19 September 2002 (2002-09-19) ct; page 5, lines 2-7; examples 1-2;

Intern I Application No
PC7/GB2004/002421

C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	PC1/GB2004/002421
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 01/58940 A (GENVEC INC) 16 August 2001 (2001-08-16) abstract; example 1; page 5, first paragraph; page 6, second paragraph, paragraph joining pages 6 and 7	·
A	PEREBOEV A V ET AL: "Coxsackievirus-adenovirus receptor genetically fused to anti-human CD40 scFv enhances adenoviral transduction of dendritic cells." GENE THERAPY. SEP 2002, vol. 9, no. 17, September 2002 (2002-09), pages 1189-1193, XP002303755 ISSN: 0969-7128 abstract; figures 1 and 3	
•		
	210 (continuation of second sheet) (January 2004)	

onal application No. PCT/GB2004/002421

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 97, 99-101 and 108 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition. In particular, the method of claim 108 is to be considered as such because it can be carried out "in vivo". 2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this International application, as follows:
see additional sheet
1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. X No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1 (partially), 2-15, 30-107 (partially)
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1 (partially), 2-15, 30-107 (partially)

Peptides comprising the motif of Seq. ID 1 (i.e. PXXXT), compositions and medical uses thereof, as well as antibodies and methods for producing said compositions: transfection mixtures, complexes, vectors, kits,...

2. claims: 1 (partially), 16-20, 30-107 (partially)

Peptides comprising the motif of Seq. ID 2 (i.e. PSXS), compositions and medical uses thereof, as well as antibodies and methods for producing said compositions: transfection mixtures, complexes, vectors, kits,...

3. claims: 1 (partially), 21-25, 30-107 (partially)

Peptides comprising the motif of Seq. ID 3 (i.e. QXXXQ), compositions and medical uses thereof, as well as antibodies and methods for producing said compositions: transfection mixtures, complexes, vectors, kits,...

4. claims: 1 (partially), 26-29, 30-107 (partially)

Peptides comprising the motif of Seq. ID 4 (i.e. SXS), compositions and medical uses thereof, as well as antibodies and methods for producing said compositions: transfection mixtures, complexes, vectors, kits,...

5. claim: 108

Method for the identification of siRNAs.

ormation on patent family members

Interr Application No
PC1/GB2004/002421

	ent document n search report		Publication date		Patent family member(s)		Publication date
WO S	9844121	A	08-10-1998	FR FR AU CA EP WO JP US	741728 7054798	A1 B2 A A1 A1 A1 T B1	09-10-1998 09-10-1998 06-12-2001 22-10-1998 08-10-1998 12-04-2000 08-10-1998 13-11-2001 27-05-2003 18-09-2003
WO (02057445	Α	25-07-2002	AU WO WO CA CA EP US	6885501 0190190 02057445 2380443 2441903 1328626 2003190598 2004161738	A2 A1 A1 A1 A1 A1	03-12-2001 29-11-2001 25-07-2002 29-11-2001 25-07-2002 23-07-2003 09-10-2003 19-08-2004
WO (03004646	A	16-01-2003	CA EP WO US CA EP WO US	2443644 1419252 03004646 2003211476 2451741 1432729 03004517 2003096354	A2 A1 A1 A2 A2	16-01-2003 19-05-2004 16-01-2003 13-11-2003 16-01-2003 30-06-2004 16-01-2003 22-05-2003
DE :	19845251	Α.	09-03-2000	DE WO EP	19845251 0014215 1109897	A1	09-03-2000 16-03-2000 27-06-2001
WO (03008537	A	30-01-2003	CA EP WO WO US	03008537 02081646	A2 A2 A2 A1	17-10-2002 28-01-2004 30-01-2003 17-10-2002 27-11-2003 24-07-2003
WO !	9118010	A	28-11-1991	AU WO	7869191 9118010		10-12-1991 28-11-1991
WO 9	9854347	A	03-12-1998	AU CA EP WO JP US US		A1 A1 A1 T A1	30-12-1998 03-12-1998 31-05-2000 03-12-1998 22-01-2002 16-01-2003 11-04-2002
WO	02072616	A	19-09-2002	CA EP WO JP US	02072616 2004532197	A1 A2 A2 T A1	19-09-2002 10-12-2003 19-09-2002 21-10-2004 08-07-2004
WO	0158940	A	16-08-2001	AU	3498101	. — — —	20-08-2001

rmation on patent family members

Intern: al Application No
PC7/682004/002421

Patent document	Publication		Patent family		Publication
Patent document cited in search report	date		Patent family member(s)		.date
WO 0158940 A		WO US	0158940 2001047081	A2 A1	16-08-2001 29-11-2001
*****	,				
		•			
				-	